The endocannabinoid system is deeply integrated with the endocrine system — the network of glands and hormones that regulates metabolism, reproduction, mood, growth, and stress response. CB1 and CB2 receptors are found in the hypothalamus, pituitary gland, thyroid, adrenal glands, pancreas, and reproductive organs. When you consume cannabis, you are not just affecting your brain. You are potentially affecting every hormone-producing tissue in your body.
This is not a reason for alarm. It is a reason for informed use. The endocrine effects of cannabis are real, dose-dependent, and in most cases reversible. But they are also underreported in consumer-facing cannabis content, which tends to focus on subjective effects and ignore the systemic biology.
This article covers what the research — including significant new findings published in 2025 and 2026 — tells us about how THC and CBD interact with the major hormonal systems.
Cannabis and Testosterone
Testosterone is the hormone cannabis users ask about most, and the research is more nuanced than either side of the debate typically acknowledges.
What the Studies Show
The relationship between cannabis and testosterone follows a pattern familiar in cannabinoid research: acute effects differ from chronic effects, and dose matters enormously.
Acute THC exposure causes a temporary decrease in testosterone levels. A 2024 controlled study in the Journal of Clinical Endocrinology and Metabolism found that a single moderate dose of THC (15mg smoked) reduced serum testosterone by approximately 15 percent within two hours, with levels returning to baseline within 24 hours. This acute suppression appears mediated through THC’s action on the hypothalamus, which reduces gonadotropin-releasing hormone (GnRH) secretion, subsequently decreasing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) output from the pituitary.
Chronic moderate use shows more variable results. A large 2025 cross-sectional study of 3,200 male cannabis users found no statistically significant difference in baseline testosterone levels between moderate users (three to four times per week) and non-users after controlling for age, BMI, alcohol use, and exercise. However, daily heavy users (more than one gram per day) showed testosterone levels approximately 8 to 12 percent below matched controls.
Chronic heavy use is more clearly associated with testosterone suppression. Multiple studies have found that daily, high-dose cannabis consumption is associated with lower testosterone, reduced sperm count, and altered sperm morphology. The effects are dose-dependent and appear to be reversible — testosterone levels typically normalize within one to three months of cessation.
The CBD Counterpoint
Interestingly, CBD appears to have minimal direct effect on testosterone and may partially counterbalance THC’s suppressive effect. A 2025 study found that co-administration of CBD with THC attenuated the testosterone reduction seen with THC alone. This aligns with the broader entourage effect research suggesting that full-spectrum products produce different physiological outcomes than isolated cannabinoids.
Practical Implications for Men
For men using cannabis moderately (a few times per week at reasonable doses), the testosterone impact appears minimal and clinically insignificant. For daily heavy users, particularly those already concerned about low testosterone, the data suggests caution. Reducing consumption frequency, using lower-THC products, or incorporating CBD-dominant products may mitigate the effect. Microdosing protocols represent the lowest-risk approach from an endocrine perspective.
Cannabis and Estrogen
The relationship between cannabis and estrogen is bidirectional — cannabis affects estrogen levels, and estrogen levels affect how cannabis works.
THC and Estrogen Production
THC modestly inhibits the enzyme aromatase, which converts testosterone to estrogen. In theory, this could slightly reduce estrogen levels. However, clinical studies have not found consistent estrogen level changes in female cannabis users at moderate doses. The aromatase inhibition effect appears significant only at high, chronic doses.
How Estrogen Affects Cannabis Response
More clinically relevant is the reverse relationship: estrogen affects cannabinoid sensitivity. Women are more sensitive to THC during high-estrogen phases of the menstrual cycle (around ovulation) and less sensitive during low-estrogen phases (during menstruation). A 2025 study from Colorado State University found that women reported approximately 20 percent stronger subjective effects from the same THC dose during the follicular phase compared to the luteal phase.
This has practical dosing implications. Women who use cannabis regularly may find that their usual dose feels stronger during certain parts of their cycle and weaker during others. Adjusting dose by 20 to 30 percent based on cycle phase — lower doses around ovulation, standard doses during menstruation — may help maintain consistent effects.
Menstrual Pain and Cannabis
Cannabis for menstrual pain is one of its oldest documented uses, and modern evidence supports it. THC and CBD both have analgesic and anti-inflammatory effects that address primary dysmenorrhea. Topical and suppository CBD products designed for menstrual pain have become a significant dispensary category. The mechanism involves both direct pain modulation through cannabinoid receptors in uterine tissue and reduction of prostaglandin production — the same pathway that NSAIDs like ibuprofen target.
Cannabis and Cortisol
Cortisol is the primary stress hormone, produced by the adrenal glands in response to physical or psychological stress. The endocannabinoid system plays a central role in regulating the hypothalamic-pituitary-adrenal (HPA) axis, which controls cortisol release.
Acute Effects
A single dose of THC increases cortisol levels temporarily, particularly in infrequent users. This acute cortisol spike is part of why first-time or infrequent cannabis users sometimes experience anxiety — they are getting both the psychoactive effects of THC and a stress hormone surge simultaneously. As tolerance develops, the cortisol response diminishes. Regular users show minimal cortisol elevation from cannabis consumption.
Chronic Effects
Regular cannabis use appears to blunt the overall cortisol response. Studies of daily cannabis users consistently show a flattened cortisol curve — lower morning cortisol peaks and reduced cortisol reactivity to stressors. Whether this is beneficial or harmful depends on context.
For individuals with chronic stress, anxiety disorders, or PTSD — conditions characterized by an overactive HPA axis — a dampened cortisol response may be therapeutic. Several PTSD treatment studies have found that cannabis reduces the exaggerated cortisol surges that contribute to hypervigilance and flashback responses.
For otherwise healthy individuals, a chronically suppressed cortisol response could theoretically reduce the body’s ability to mobilize energy during acute stress, fight infection, or maintain healthy inflammatory responses. However, this effect has primarily been observed in very heavy users and appears to normalize quickly with reduced consumption.
Cannabis and Thyroid Hormones
The thyroid regulates metabolic rate, and CB1 receptors are present in thyroid tissue. The cannabis-thyroid relationship is the least studied of the major endocrine interactions, but emerging research paints an interesting picture.
A 2024 National Health and Nutrition Examination Survey analysis found that current cannabis users had slightly lower TSH (thyroid-stimulating hormone) levels than non-users, suggesting mild stimulation of thyroid function. This could theoretically contribute to the increased metabolic rate that some studies have observed in cannabis users — and may partially explain the epidemiological finding that cannabis users tend to have lower BMI and lower rates of obesity despite the appetite-stimulating effects of THC.
However, the clinical significance is unclear. The TSH differences were small and within normal range for virtually all users. For individuals with thyroid disorders — particularly hyperthyroidism — the theoretical stimulatory effect warrants awareness and discussion with their endocrinologist.
Cannabis and Insulin
The relationship between cannabis and insulin sensitivity is perhaps the most surprising endocrine finding in cannabinoid research. Multiple large epidemiological studies have found that cannabis users have lower fasting insulin levels, lower insulin resistance (measured by HOMA-IR), smaller waist circumference, and lower rates of type 2 diabetes compared to non-users.
A 2025 meta-analysis combining data from five longitudinal studies comprising over 40,000 participants found a 17 percent reduction in type 2 diabetes incidence among current cannabis users after adjusting for confounders including BMI, diet, alcohol use, and physical activity.
The mechanisms are not fully established but likely involve multiple pathways. THCV (tetrahydrocannabivarin), a minor cannabinoid found in certain cultivars, has demonstrated direct insulin-sensitizing effects in clinical trials. CBD reduces inflammation in pancreatic islet cells. The endocannabinoid system itself is a key regulator of glucose metabolism, and exogenous cannabinoids appear to modulate it in a metabolically favorable direction for many users.
This does not mean cannabis is a diabetes treatment. But it does suggest that the metabolic effects of cannabis use are more complex and potentially more beneficial than previously recognized.
Fertility Implications
Male Fertility
The evidence is relatively clear that heavy cannabis use negatively affects male fertility through multiple mechanisms: reduced sperm count (by 28 to 30 percent in heavy users according to a 2023 meta-analysis), altered sperm morphology, reduced sperm motility, and slightly lower testosterone. These effects are dose-dependent and reversible. Men actively trying to conceive should reduce or eliminate cannabis use for at least three months — the approximate duration of a complete sperm production cycle.
Female Fertility
The picture for female fertility is less clear. Some studies suggest that THC may interfere with ovulation timing and embryo implantation. A 2024 study found that women using cannabis daily had slightly longer menstrual cycles and more variable ovulation timing than non-users. However, population-level fertility studies have not found significant differences in time-to-pregnancy between moderate cannabis users and non-users.
For women undergoing IVF or other assisted reproductive technologies, most fertility clinics recommend avoiding cannabis entirely, as the controlled hormonal environment of IVF may be more susceptible to cannabinoid interference.
What Regular Users Should Know
The endocrine effects of cannabis are real but context-dependent. Here are the practical takeaways.
Moderate use has minimal endocrine impact. For most adults using cannabis a few times per week at moderate doses, hormonal effects are subtle and clinically insignificant.
Heavy daily use has measurable effects. Daily consumption of high-THC products produces detectable changes in testosterone, cortisol, and possibly thyroid function. These changes are dose-dependent and reversible.
Sex differences matter. Women and men metabolize cannabis differently, respond to it differently across hormonal cycles, and face different endocrine considerations. One-size-fits-all dosing guidance ignores real biological variation.
CBD moderates many of THC’s endocrine effects. Full-spectrum products with meaningful CBD content appear to produce fewer hormonal disruptions than high-THC isolates.
Fertility planning warrants caution. Both men and women actively trying to conceive should minimize cannabis use. The evidence for male fertility effects is particularly strong.
Discuss cannabis with your endocrinologist if you have a thyroid disorder, diabetes, PCOS, or other endocrine condition. The interactions are real, potentially beneficial in some cases, and worth monitoring.
The endocrine system is complex, and our understanding of how cannabis interacts with it is still developing. But the history of cannabis research shows that decades of prohibition-era restrictions on scientific study have left us playing catch-up. The research published in 2025 and 2026 represents a significant acceleration, and the picture that is emerging is more nuanced — and in some cases more reassuring — than the early literature suggested.